Acute Heart Failure Clinical Trial
— SSU-AHFOfficial title:
Using Short Stay Units Instead of Routine Admission to Improve Patient Centered Health Outcomes for AHF Patients
Verified date | August 2023 |
Source | Indiana University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The majority of the over one million annual AHF hospitalizations originate from the emergency department. Admitting and re-admitting lower risk AHF patients who don't need prolonged hospitalization may increase their risk for poor outcomes and decrease their quality of life: Safe alternatives to hospitalization from the ED are needed. We propose a strategy-of-care, short stay unit management of AHF (i.e. less than 24 hours), will lead to improved outcomes for lower risk AHF patients.
Status | Completed |
Enrollment | 194 |
Est. completion date | July 22, 2021 |
Est. primary completion date | July 22, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 99 Years |
Eligibility | Inclusion: 1. ED physician clinical diagnosis of AHF; 2. Planned admission for AHF 3. Systolic blood pressure > 100mmHg, heart rate < 115bpm* 4. Previous history of HF *Patients with atrial fibrillation but controlled HR are eligible For Caregiver Burden assessments. The eligibility criteria for a caregiver: 1) person either self-identifies, or when asked identifies themselves, as the primary caregiver for the patient. If there are multiple caregivers, the person who self-identifies as providing the most care will be asked to provide verbal informed consent. Exclusion: 1. Transplanted organ of any kind or ventricular assist device patient; 2. End stage renal disease, on dialysis, or eGFR < 20 mL/min; 3. Acute coronary syndrome (e.g. EKG changes consistent with ischemia or troponin elevation secondary to ACS); 4. Other acute co-morbid conditions (e.g. sepsis, altered mental status) that are unlikely to be treated within a SSU stay; 5. Patients who require ventilatory support of any kind or intravenous vasodilators/vasopressor/inotropic support. Patients who receive a one-time dose of an intravenious vasodiolator, but are no longer on this medication, are eligible. 6. Pregnant patients or any patient who has been pregnant in the last 3 months 7. < 18 years of age 8. Any patient who in the opinion of the clinician or investigator requires hospitalization or ICU level care or will require rehabilitation or skilled nursing after discharge from the ED or hospital 9. Planned discharge from the emergency department 10. Patients hospitalized within the last 30 days ONLY if the institution mandates these patients are observed. Otherwise these patients are eligible. 11. De Novo (new Onset) AHF |
Country | Name | City | State |
---|---|---|---|
United States | University of Alabama - Birmingham | Birmingham | Alabama |
United States | Ohio State University | Columbus | Ohio |
United States | UT Southwestern Medical Center | Dallas | Texas |
United States | Henry Ford Health System | Detroit | Michigan |
United States | Indiana University | Indianapolis | Indiana |
United States | University of Mississippi Medical Center | Jackson | Mississippi |
United States | Vanderbilt University Medical Center | Nashville | Tennessee |
United States | Allegheny Health Network | Pittsburgh | Pennsylvania |
United States | Beaumont Health System | Royal Oak | Michigan |
United States | Washington University | Saint Louis | Missouri |
United States | Wake Forest School of Medicine | Winston-Salem | North Carolina |
Lead Sponsor | Collaborator |
---|---|
Indiana University | Agency for Healthcare Research and Quality (AHRQ) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Caregiver Burden | Measure caregiver burden | 30 and 90 days | |
Other | Cost Effectiveness Analysis | Determine differences in costs between the two strategy of care arms | 90 days | |
Other | Modified Resource Utilization Questionnaire for Heart Failure | Measures resource utilization | 30 days | |
Other | All cause mortality and re-hospitalization | Assessment of time to event for this composite outcome | 30 and 90 days from randomization | |
Other | Days alive and out of hospital | To demonstrate the effectiveness of a SSU AHF management strategy vs standard of care | 90 days | |
Primary | Days alive and out of hospital | To demonstrate the effectiveness of a SSU AHF management strategy vs standard of care | 30 day outcome | |
Secondary | Quality of life as measured by Kansas City Cardiomyopathy Questionnaire | To determine quality of life using a heart failure questionnaire | 30 day outcome | |
Secondary | Cost Effectiveness Analysis | Determine differences in costs between the two strategy of care arms | 30 day outcome |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT02151383 -
Pharmacokinetics & Safety of Serelaxin on Top of Standard of Care Therapy in Pediatric Patients With Acute Heart Failure
|
Phase 2 | |
Completed |
NCT02135835 -
A Study to Evaluate the Efficacy and Safety of Shenfu Zhusheye in Patients With Acute Heart Failure
|
Phase 4 | |
Recruiting |
NCT05556044 -
Empagliflozin for New On-set Heart Failure Study Regardless of Ejection Fraction
|
Phase 3 | |
Recruiting |
NCT04363697 -
Dapagliflozin and Effect on Cardiovascular Events in Acute Heart Failure -Thrombolysis in Myocardial Infarction 68 (DAPA ACT HF-TIMI 68)
|
Phase 4 | |
Completed |
NCT02122640 -
Evaluation of Acute Cardiogenic Dyspnoea With Thorax Echography and Pro-BNP in the Emergency Department
|
N/A | |
Not yet recruiting |
NCT01211886 -
Utility of Brain Natriuretic Peptide (BNP) in Patients With Type IV Cardio-renal Syndrome Admitted to the Intensive Care Unit (ICU)
|
N/A | |
Completed |
NCT01193998 -
Impact of Validated Diagnostic Prediction Model of Acute Heart Failure in the Emergency Department
|
N/A | |
Not yet recruiting |
NCT06465498 -
Investigating aCute heArt failuRe Decongestion Guided by Lung UltraSonography
|
N/A | |
Recruiting |
NCT05276219 -
Optimized Treatment of Pulmonary Edema or Congestion
|
Phase 4 | |
Recruiting |
NCT05392764 -
Early Treatment With a Sodium-glucose Co-transporter 2 Inhibitor in High-risk Patients With Acute Heart Failure
|
Phase 3 | |
Recruiting |
NCT03157219 -
Manipal Heart Failure Registry (MHFR)
|
N/A | |
Completed |
NCT06024889 -
Acute Effects of Furosemide on Hemodynamics and Pulmonary Congestion in Acute Decompensated Heart Failure.
|
Phase 1/Phase 2 | |
Terminated |
NCT04174794 -
Investigating Reduction of aCute heArt Failure Readmission With Lung UltraSound-preliminary Trial
|
||
Recruiting |
NCT05972746 -
Telemonitoring Program in the Vulnerable Phase After Hospitalization for Heart Failure
|
N/A | |
Enrolling by invitation |
NCT02258984 -
Can the Venus 1000 Help Clinicians Treat Patients With Severe Sepsis or Acute Heart Failure? The CVP Trial
|
N/A | |
Completed |
NCT02141607 -
Evolution of Molecular Biomarkers in Acute Heart Failure Induced by Shock
|
||
Completed |
NCT01870778 -
Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF
|
Phase 3 | |
Recruiting |
NCT05986773 -
Diuretic Strategies in Acute Heart Failure Patients at High Risk for Diuretic Resistance
|
Phase 4 | |
Recruiting |
NCT04163588 -
Sequential Nephron Blockade in Acute Heart Failure
|
Phase 3 | |
Recruiting |
NCT03720288 -
Acetazolamide in Patients With Acute Heart Failure
|
Phase 3 |